Study Stopped
No more participants enrolled.
The Effect of Bispectral Index Monitoring on Recovery From Deep Sedation
1 other identifier
observational
12
1 country
1
Brief Summary
The purpose of this study was to compare BIS (bispectral index) monitoring and clinical sedation scale assessment on the recovery time and propofol usage from deep propofol sedation in children with cerebral palsy who received botulinum toxin injection.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started May 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 4, 2019
CompletedFirst Posted
Study publicly available on registry
December 9, 2019
CompletedStudy Start
First participant enrolled
May 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 9, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 9, 2022
CompletedFebruary 15, 2023
February 1, 2023
1.6 years
December 4, 2019
February 13, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
recovery
Time taken to recover based on the Physiological CBD score (\>12) from deep sedation
Immediately after discontinuation of propofol infusion used for botulinum toxin injection
Secondary Outcomes (1)
Propofol dose
Immediately after discontinuation of propofol infusion used for botulinum toxin injection
Study Arms (2)
Group Control
Group who maintains deep sedation using the University of Michigan sedation scale (UMSS) score.
Group BIS
Group who maintain deep sedation using Bispectral Index (BIS) score.
Eligibility Criteria
children with spastic cerebral palsy primary care clinic (rehabilitation)
You may qualify if:
- years old children with spastic cerebral palsy receiving botulinum toxin injection with deep sedation
- American Society of Anesthesiologists Physical Status 1-2
You may not qualify if:
- Body mass index \> 30 kg/m2
- unstable heart disease
- Anticipated difficult airway including congenital facial or airway anomaly
- Recent upper respiratory tract infection ( \< 2 weeks)
- Gastroesophageal reflux
- Allergy history to propofol, remifentanil or any drug used during procedure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Location Yeungnam University Hospita
Daegu, 42415, South Korea
Related Publications (3)
Choudhry DK, Brenn BR. Bispectral index monitoring: a comparison between normal children and children with quadriplegic cerebral palsy. Anesth Analg. 2002 Dec;95(6):1582-5, table of contents. doi: 10.1097/00000539-200212000-00020.
PMID: 12456420RESULTMalviya S, Voepel-Lewis T, Tait AR. A comparison of observational and objective measures to differentiate depth of sedation in children from birth to 18 years of age. Anesth Analg. 2006 Feb;102(2):389-94. doi: 10.1213/01.ANE.0000184045.01780.73.
PMID: 16428530RESULTSaricaoglu F, Celebi N, Celik M, Aypar U. The evaluation of propofol dosage for anesthesia induction in children with cerebral palsy with bispectral index (BIS) monitoring. Paediatr Anaesth. 2005 Dec;15(12):1048-52. doi: 10.1111/j.1460-9592.2005.01658.x.
PMID: 16324022RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sung Mee Jung, MD,PhD
Yeungnam University Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 4, 2019
First Posted
December 9, 2019
Study Start
May 1, 2021
Primary Completion
December 9, 2022
Study Completion
December 9, 2022
Last Updated
February 15, 2023
Record last verified: 2023-02
Data Sharing
- IPD Sharing
- Will not share
no plan to share our data